Free Trial

4D Molecular Therapeutics (FDMT) Competitors

4D Molecular Therapeutics logo
$4.22 +0.27 (+6.84%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$4.24 +0.02 (+0.47%)
As of 07/8/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FDMT vs. GHRS, SNDX, IMNM, GYRE, VIR, DNA, XERS, REPL, PHAR, and SANA

Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), Gyre Therapeutics (GYRE), Vir Biotechnology (VIR), Ginkgo Bioworks (DNA), Xeris Biopharma (XERS), Replimune Group (REPL), Pharming Group (PHAR), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

4D Molecular Therapeutics vs. Its Competitors

GH Research (NASDAQ:GHRS) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

56.9% of GH Research shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GH Research has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.81, meaning that its share price is 181% more volatile than the S&P 500.

GH Research presently has a consensus target price of $32.00, indicating a potential upside of 121.15%. 4D Molecular Therapeutics has a consensus target price of $29.56, indicating a potential upside of 600.37%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than GH Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GH Research
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
4D Molecular Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than GH Research. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 5 mentions for GH Research. GH Research's average media sentiment score of 0.34 beat 4D Molecular Therapeutics' score of 0.07 indicating that GH Research is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GH Research
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
4D Molecular Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GH Research has higher earnings, but lower revenue than 4D Molecular Therapeutics. GH Research is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GH ResearchN/AN/A-$38.96M-$0.79-18.32
4D Molecular Therapeutics$40K4,887.82-$160.87M-$3.18-1.33

GH Research has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. GH Research's return on equity of -19.20% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
GH ResearchN/A -19.20% -18.40%
4D Molecular Therapeutics -767,126.06%-33.26%-30.68%

Summary

GH Research and 4D Molecular Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDMT vs. The Competition

Metric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$182.98M$2.68B$5.50B$8.94B
Dividend YieldN/A1.79%5.25%4.04%
P/E Ratio-1.338.9826.9720.11
Price / Sales4,887.82714.59426.02119.76
Price / CashN/A159.8036.8257.86
Price / Book0.384.517.985.56
Net Income-$160.87M$31.26M$3.16B$248.40M
7 Day Performance-2.09%3.57%2.36%4.67%
1 Month Performance-11.90%1.28%2.15%6.64%
1 Year Performance-81.40%1.08%33.78%21.31%

4D Molecular Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDMT
4D Molecular Therapeutics
2.2773 of 5 stars
$4.22
+6.8%
$29.56
+600.4%
-80.4%$182.98M$40K-1.33120
GHRS
GH Research
1.5694 of 5 stars
$15.01
+0.7%
$32.00
+113.2%
+31.8%$776MN/A-19.0010
SNDX
Syndax Pharmaceuticals
3.1623 of 5 stars
$8.73
-3.0%
$35.80
+310.1%
-58.6%$774.43M$23.68M-2.26110
IMNM
Immunome
2.6048 of 5 stars
$8.69
-1.7%
$23.33
+168.5%
-29.9%$769.19M$9.04M-2.7340
GYRE
Gyre Therapeutics
0.0861 of 5 stars
$7.62
-6.3%
N/A-33.2%$762.25M$105.76M381.1940
VIR
Vir Biotechnology
3.1902 of 5 stars
$5.27
-2.6%
$32.86
+523.5%
-37.1%$747.87M$74.21M-1.25580Positive News
DNA
Ginkgo Bioworks
1.2448 of 5 stars
$11.38
-10.5%
$5.77
-49.3%
N/A$744.53M$227.04M-1.24640Positive News
XERS
Xeris Biopharma
3.7184 of 5 stars
$4.70
-1.1%
$6.25
+33.0%
+123.9%$742.83M$203.07M-15.67290Positive News
REPL
Replimune Group
4.1678 of 5 stars
$9.65
+2.7%
$20.83
+115.9%
+10.7%$724.61MN/A-3.14210High Trading Volume
PHAR
Pharming Group
2.7722 of 5 stars
$10.47
-1.0%
$30.00
+186.5%
+24.4%$719.77M$297.20M-52.35280Gap Down
SANA
Sana Biotechnology
2.5683 of 5 stars
$3.10
-2.8%
$9.17
+195.7%
-23.4%$719.27MN/A-3.52380Gap Up

Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners